Vol 8, No 1 (2012)
Review paper
Published online: 2012-03-29
Diffuse large B-cell lymphoma in elderly
Onkol. Prak. Klin 2012;8(1):36-40.
Abstract
Approximately 30% of patients with diffuse large B-cell lymphoma (DLBCL) are older than 70 years. Rituximab
added to CHOP remains standard protocol in elderly patients except for those with severe comorbidities.
Treatment with R-CHOP in elderly is complicated by substantial myelotoxicity and doxorubicin
induced cardiotoxicity. Therefore supportive care including granulocytes growth factors administration is
mandatory. This article summarizes possibilities of optimization of therapy of DLBCL in elderly.
added to CHOP remains standard protocol in elderly patients except for those with severe comorbidities.
Treatment with R-CHOP in elderly is complicated by substantial myelotoxicity and doxorubicin
induced cardiotoxicity. Therefore supportive care including granulocytes growth factors administration is
mandatory. This article summarizes possibilities of optimization of therapy of DLBCL in elderly.
Keywords: diffuse large B-cell lymphomatherapyelderly